Conzerol zero molluscum contagiosum — Class II drug recall D-0261-2023
Terminated recall by DISCOVERY PHARMA LLC, reported 2023-02-08, distributed in CA, FL, WA. CGMP deviations
| Recall number | D-0261-2023 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | DISCOVERY PHARMA LLC, Oviedo, FL, United States |
| Recall initiated | 2022-11-09 |
| Classified | 2023-02-01 |
| Reported by FDA | 2023-02-08 |
| Terminated | 2024-04-29 |
| Distributed | CA, FL, WA |
| Quantity | 21,892 tubes |
| Reason classes | cgmp |
| UPC / GTIN / UDI-DI | 00860322001808 |
| Lot numbers | 21732, 22123 |
| Expiration dates | 2023-07, 2024-01 |
Product
Conzerol zero molluscum contagiosum, Homeopathic treatment for Molluscum Contagiosum, Topical Cream, Net weight 0.78 oz (22g) tube, UPC 8 60322 00180 8, Manufactured by: Dr. Retter EC Warszawska 17, 05-075 Warszawa Poland
Reason for recall
CGMP deviations
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0261-2023. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.